ArticleThe Journal of clinical investigation2006
CD137-mediated immunotherapy for allergic asthma.
Article in The Journal of clinical investigation, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 90 citations in OpenAlex.
- Single-cell transcriptome sequencing reveals immunological mechanisms by which recombinant Echinococcus granulosus P29 protein alleviates airway inflammation in mice with allergic asthma.Parasites & vectors · 2026Article
- CAR-NKT Cells in Asthma: Use of NKT as a Promising Cell for CAR Therapy.Clinical reviews in allergy & immunology · 2024Review
- Agonism of 4-1BB for immune therapy: a perspective on possibilities and complications.Frontiers in immunology · 2023Review
- Immune checkpoint molecules in prevention and development of asthma.Frontiers in immunology · 2023Review
- Tim-3 is dispensable for allergic inflammation and respiratory tolerance in experimental asthma.PloS one · 2021Article
- Cutaneous vaccination with coated microneedles prevents development of airway allergy.Journal of controlled release : official journal of the Controlled Release Society · 2017Article
- Short-term intratracheal use of PEG-modified IL-2 and glucocorticoid persistently alleviates asthma in a mouse model.Scientific reports · 2016Article
- Effect of TH2 cytokines and interferon gamma on beat frequency of human respiratory cilia.Pediatric research · 2016Article
- CD137 and CD137L signals are main drivers of type 1, cell-mediated immune responses.Oncoimmunology · 2016Review
- Blocking the 4-1BB Pathway Ameliorates Crystalline Silica-induced Lung Inflammation and Fibrosis in Mice.Theranostics · 2016Article
- Critical role for syndecan-4 in dendritic cell migration during development of allergic airway inflammation.Nature communications · 2015Article
- Association of serum interleukin-27 with the exacerbation of chronic obstructive pulmonary disease.Physiological reports · 2014Article
- Galectin-9 controls the therapeutic activity of 4-1BB-targeting antibodies.The Journal of experimental medicine · 2014Article
- Lifetime-dependent effects of bisphenol A on asthma development in an experimental mouse model.PloS one · 2014Article
- CD137 deficiency does not affect development of airway inflammation or respiratory tolerance induction in murine models.Clinical and experimental immunology · 2012Article
- Reverse signaling through the costimulatory ligand CD137L in epithelial cells is essential for natural killer cell-mediated acute tissue inflammation.Proceedings of the National Academy of Sciences of the United States of America · 2012Article
- Volatile organic compounds enhance allergic airway inflammation in an experimental mouse model.PloS one · 2012Article
- 4-1BB signaling breaks the tolerance of maternal CD8+ T cells that are reactive with alloantigens.PloS one · 2012Article
- Hu.4-1BB-Fc fusion protein inhibits allergic inflammation and airway hyperresponsiveness in a murine model of asthma.Korean journal of pediatrics · 2011Article
- MicroRNAs profiling in murine models of acute and chronic asthma: a relationship with mRNAs targets.PloS one · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The prevalence of asthma continues to increase. Asthma is caused by a Th2 cell-driven immune response. Its optimal treatment remains a challenge, and a sufficient immunotherapeutic approach to treating asthma has yet to be found. Using a murine asthma model, we show that a single injection of an anti-CD137 (4-1BB) mAb prevents the development of airway hyperreactivity, eosinophilic airway inflammation, excessive mucus production, and elevated IgE during the observation period of 7 weeks. Most importantly, even established disease is completely reversed by anti-CD137 mAb administration. The protection is associated with markedly reduced Th2 cytokine production and increased secretion of the Th1 cytokine IFN-gamma. While B lymphocytes are partly depleted, the number of CD8+ T cells is increased. Blockade of IFN-gamma and depletion of CD8+ T cells during treatment with anti-CD137 mAb reduces in part but does not abrogate the protective effect of CD137 mAb. In contrast, CD137 mAb-mediated CD4+ T cell anergy is critical for the observed effects, since transfer of CD4+ T cells from CD137 mAb-treated mice conveyed protection. These data demonstrate, for the first time to our knowledge, the capacity of anti-CD137 mAb to ameliorate allergic asthma, and they indicate CD137 as a possible target for therapeutic intervention in this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.